<DOC>
	<DOCNO>NCT01225835</DOCNO>
	<brief_summary>This study aim demonstrate highly purify Menotrophin produce significant low progesterone serum level follicular phase comparison Follitropin alpha treatment subfertile female undergo vitro fertilisation ( IVF ) investigate progesterone serum level might useful predictor success rate ongoing pregnancy rate</brief_summary>
	<brief_title>Progesterone Serum Levels Subfertile Female Patients Undergoing Vitro Fertilisation ( IVF )</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Signed informed consent Subfertile premenopausal female patient eligible vitro fertilisation ( IVF ) treatment Aged ≥34 ≤42 year Body mass index &gt; 18 &lt; 28 kg/m^2 Normal pelvic ultrasound Screening No two previous gonadotrophin stimulate cycle IVF intracytoplasmic sperm injection ( ICSI ) history infertility treatment ( gonadotrophin stimulate cycle use IVF ICSI count ; Clomifen cycle exclusion criterion ) At least 3 consecutive ovulatory menstrual cycle 2435 day No fertility stimulate drug Sperm partner classify normal accord World Health Organisation ( WHO ) 2010 criterion Clinically normal baseline haematology , clinical chemistry , urinalysis value Negative serum Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) antibody test within last 6 month prior Screening Endocrine test result within clinically normal limit Screening Presence clinically relevant systemic disease ( e.g. , insulindependent diabetes mellitus ) A history current endocrine disease ( exclude treat hypothyreosis ) , include polycystic ovary syndrome ( PCOS ) hyperprolactinaemia A history coagulation disorder Persistent ovarian cyst ( &gt; 3 month ) A history hypersensitivity constituent study medication relate compound Diagnosed poor ( &lt; 3 oocyte ) responder prior gonadotrophin stimulated ARTcycle History severe ovarian hyperstimulation syndrome former gonadotrophin stimulate assisted reproductive technology ( ART ) cycle</criteria>
	<gender>Female</gender>
	<minimum_age>34 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>